⚠ Evidence warning: Clinical trials or other evidence do not support the claim that daily willow bark prevents migraine and chronic tension headache, alone or in a magnesium, riboflavin, coenzyme Q10 and feverfew protocol, or helps break medication-overuse headache: no controlled trial of willow bark for headache has been published, and the 2012 neurology guideline found the data for aspirin in migraine prevention conflicting or inadequate. This page keeps it as a report of what people, websites or other media say.

Willow Bark for Headache and Migraine

Headache and Migraine — scientific infographic poster

Willow bark has been used as a headache remedy for at least 2,400 years — Hippocrates' "powder of willow" was prescribed for cephalalgia in 5th-century-BCE Greece — and the usual explanation is that salicin-derived salicylic acid produces the same cyclooxygenase inhibition that makes aspirin effective for tension headache, although a 2001 study found that a 240 mg salicin dose yields far less salicylic acid than an analgesic aspirin dose. The catch is timing. Willow's indirect metabolism (intestinal hydrolysis, hepatic oxidation) delays peak blood salicylate to up to 2 hours after dosing, compared with 30-45 minutes for aspirin. For acute headache, this is a meaningful disadvantage. For chronic tension-pattern headache or migraine prophylaxis combined with feverfew, magnesium, and riboflavin, practitioners find willow's longer-duration, gastrointestinal-gentler profile more attractive; willow bark alone has not been tested in a controlled headache trial. This deep-dive walks through traditional use, the limited but encouraging modern pilot data, head-to-head comparison with aspirin and acetaminophen, and how to think about willow bark in modern headache management.


Table of Contents

  1. 2,400 Years of Traditional Use for Headache
  2. Mechanism for Headache
  3. Tension Headache
  4. Migraine
  5. Acute Treatment vs Prophylactic Use
  6. Willow Bark vs Aspirin for Headache
  7. Willow Bark vs Acetaminophen for Headache
  8. Combination Protocols for Migraine Prevention
  9. Medication Overuse Headache
  10. Dosing for Headache
  11. Cautions
  12. Key Research Papers
  13. Connections
  14. Featured Videos

2,400 Years of Traditional Use for Headache

Headache is one of the oldest documented indications for willow bark in Western medicine. Hippocrates of Cos (c. 460-370 BCE) recommended willow leaves and willow bark for cephalalgia (headache), gynecological pain in labor, and fever. The Hippocratic prescription — chew the bitter young bark or brew a tea from the powdered older bark — was carried forward by Dioscorides in the 1st century CE and remained a staple of Western herbal medicine through the medieval and early modern periods.

Independent North American ethnobotanical use is well documented: the Cherokee chewed inner willow bark for headache and toothache; the Iroquois Confederacy used Salix nigra (black willow) decoction for headache and fever; the Lenape and other Algonquian peoples used willow preparations for "head pain" and as part of fever-management compresses. The convergent discovery on two continents that willow bark relieves headache is strong evidence the effect is real and substantial — humans across cultures independently identified the same plant for the same purpose without communication.

Edward Stone's 1763 letter to the Royal Society, "An account of the success of the bark of the willow in the cure of agues", described willow bark given to about 50 patients for agues (intermittent fevers), not for headache. By the 19th century, willow bark and isolated salicin were standard analgesics in European pharmacopoeias for headache, fever, and rheumatism. Bayer's 1899 launch of aspirin (acetylsalicylic acid) was marketed heavily as a headache remedy, and aspirin's commercial success cemented salicylates as the dominant first-line headache treatment for the entire 20th century until acetaminophen (paracetamol) emerged as a comparable over-the-counter (OTC) option in the 1950s and the triptans transformed migraine-specific management starting with sumatriptan in 1991.

The historical record makes clear that willow has been used for headache continuously across 2,400 years of Western medicine. Modern willow extract preparations sit at the start of the salicylate analgesic chain that produces aspirin's headache effect — the same downstream mechanism, just with the slower-onset, gentler-on-the-stomach pharmacokinetic profile of the natural glycoside form.

Back to Table of Contents

Mechanism for Headache

Most headache pain is mediated by activation of trigeminovascular nociceptive pathways and by sensitization of central pain processing in the spinal trigeminal nucleus and thalamus. Prostaglandins, particularly PGE2 and PGI2 (prostacyclin), are key inflammatory mediators that:

Salicin-derived salicylic acid's cyclooxygenase inhibition reduces prostaglandin synthesis, which interrupts this cascade at several steps. Plus, the willow polyphenol fraction's NF-kappaB inhibition reduces the inflammatory upregulation of cyclooxygenase-2 (COX-2) in stressed brain tissue and reduces secondary cytokine production that amplifies headache pain. The combined effect is a broad-spectrum reduction in headache-relevant inflammatory signaling, similar in mechanism to aspirin but somewhat broader because of the polyphenol contribution discussed in the Anti-Inflammatory deep-dive.

The key clinical caveat is timing. Willow bark's indirect metabolism — intestinal hydrolysis of salicin to saligenin, hepatic oxidation to salicylic acid — brings blood salicylate to its peak within 2 hours (Schmid 2001). Aspirin reaches peak in 30-45 minutes. For acute headache where rapid relief is the priority, aspirin's faster onset is a meaningful advantage. Herbal practitioners regard willow's slower-onset, longer-duration profile as acceptable or even preferable for chronic recurrent headache or for tension-pattern headache that builds slowly.

In an animal headache model, a 2026 rat study found that low doses of parthenolide (from feverfew) plus salicin, given daily, prevented chronic head-pain sensitivity and the rise in calcitonin gene-related peptide (CGRP) in the brainstem pain relay (trigeminocervical complex), in both male and female rats (Shrivastava 2026). These are animal data only.

Back to Table of Contents

Tension Headache

Tension-type headache (TTH) is the most common primary headache disorder, affecting 30-78% of adults at some point. Episodic tension headache (less than 15 days per month) and chronic tension headache (15 or more days per month) together account for the substantial majority of headaches in the general population. The pain is typically bilateral, pressing or tightening rather than throbbing, mild to moderate intensity, not aggravated by routine physical activity, and without prominent nausea or photophobia (which would suggest migraine instead).

The pharmacological response of tension headache to nonsteroidal anti-inflammatory drugs (NSAIDs) is well-documented: aspirin 500-1000 mg or ibuprofen 400 mg produces meaningful pain reduction in 50-60% of acute tension headache episodes within 1-2 hours. Acetaminophen 1000 mg has slightly smaller effect but is the preferred choice when nonsteroidal anti-inflammatory drug (NSAID) is contraindicated. The COX-inhibition mechanism is responsible for the analgesic effect.

Modern clinical trials specifically of willow bark for tension headache are limited — the indication has not attracted significant pharmaceutical-industry research interest because aspirin is generic, over-the-counter, fast-acting, and well-established. Practitioners describe willow bark as a slower-onset, gastrointestinal-gentler alternative to chronic nonsteroidal anti-inflammatory drug use for recurrent tension headache, on the reasoning that its salicylic acid acts like aspirin (cyclooxygenase inhibition). The measured amounts differ greatly, though: in a 2001 study of 10 volunteers, willow bark extract providing 240 mg of salicin produced an average peak of 1.2 mg/L of salicylic acid and a total salicylate exposure equal to about 87 mg of aspirin — far lower blood salicylate than analgesic doses of aspirin produce. The authors concluded that salicylic acid alone is unlikely to explain willow bark's pain-relieving effects (Schmid 2001).

Practitioners suggest that for people with chronic tension headache who take a nonsteroidal anti-inflammatory drug or aspirin daily or near-daily, switching to willow bark may reduce gastrointestinal (GI) toxicity and the risk of medication-overuse headache (see below); no trial has tested this. The slower onset of willow makes it less attractive as PRN acute treatment, but as a daily background analgesic for chronic tension headache it works through a sensible mechanism.

Back to Table of Contents

Migraine

Migraine is a different clinical entity from tension headache: typically unilateral throbbing pain, moderate to severe intensity, aggravated by routine activity, accompanied by nausea, photophobia, phonophobia, and sometimes preceded by visual or sensory aura. Migraine pathophysiology involves cortical spreading depression, trigeminovascular activation, CGRP release, and meningeal neurogenic inflammation. The triptan class (sumatriptan, rizatriptan, others) and the newer CGRP-receptor antagonists (rimegepant, ubrogepant) target migraine-specific mechanisms and are the most effective acute migraine treatments. The CGRP-antibody class (erenumab, fremanezumab, galcanezumab, eptinezumab) targets migraine prevention.

Nonsteroidal anti-inflammatory drugs and aspirin remain useful in migraine, particularly for mild-to-moderate attacks and as part of combination protocols. Aspirin 900-1000 mg (high dose) has demonstrated efficacy in randomized trials for acute migraine, particularly when combined with metoclopramide for anti-emetic effect and improved gastric absorption. Ibuprofen 600-800 mg has similar evidence.

The role of willow bark in migraine is more limited than in tension headache. The slower onset (up to 2 hours to peak blood salicylate) is a significant disadvantage for acute migraine, where the typical attack reaches peak intensity within 1-2 hours and the patient wants relief immediately. The triptan class produces meaningful relief within 30-60 minutes; even aspirin and ibuprofen at therapeutic doses act faster than willow. Willow bark has not been shown to work for acute moderate-to-severe migraine.

Its proposed role is in migraine prophylaxis: chronic daily preventive treatment intended to reduce attack frequency rather than acute symptom relief. Practitioners use willow bark as an adjunctive component of natural migraine prevention protocols, citing its slower-onset, longer-duration profile and lower gastrointestinal toxicity, particularly combined with magnesium, riboflavin (B2), coenzyme Q10 (CoQ10), and feverfew — see the combination protocols section below, which also gives each component's guideline rating.

For comprehensive migraine information see Migraine.

Back to Table of Contents

Acute Treatment vs Prophylactic Use

The acute-vs-prophylactic distinction is central to thinking about willow bark in headache management:

The integrative headache-management approach that practitioners describe has four steps:

  1. Identifying the headache pattern (episodic tension, chronic tension, episodic migraine, chronic migraine, mixed)
  2. For acute headache, a fast-onset agent matched to the headache type (aspirin or ibuprofen for tension headache; triptan for moderate-to-severe migraine; combination triptan + nonsteroidal anti-inflammatory drug for refractory acute migraine)
  3. For headache prevention (chronic tension headache or frequent migraine), willow bark as part of a daily prophylactic regimen alongside other natural preventive agents (practitioner use; not tested in controlled trials)
  4. Keeping acute-medication days low, since frequent use causes medication-overuse headache (see below)

Back to Table of Contents

Willow Bark vs Aspirin for Headache

For acute headache, aspirin has clear advantages over willow bark:

For chronic daily headache prophylaxis, the calculus shifts somewhat:

For acute migraine the trial evidence for aspirin is strong: a Cochrane review of 13 trials (4,222 people) found aspirin 900-1000 mg about as effective as sumatriptan 50 mg for 2-hour pain freedom and headache relief, and adding metoclopramide 10 mg reduced nausea and vomiting compared with aspirin alone (Kirthi 2013).

In summary: aspirin has the trial evidence for acute headache treatment in adults without contraindications. Willow bark is used by practitioners for chronic prophylactic use, particularly when chronic nonsteroidal anti-inflammatory drug gastrointestinal toxicity is a concern, without controlled headache trials.

Back to Table of Contents

Willow Bark vs Acetaminophen for Headache

Acetaminophen (paracetamol) is the other common over-the-counter headache analgesic and is mechanistically quite different from both willow bark and aspirin. Acetaminophen produces analgesic and antipyretic effect through central nervous system mechanisms that are only partially understood — it weakly inhibits central nervous system (CNS) cyclooxygenase (particularly the COX-3 splice variant in brain), activates descending serotonergic and cannabinoid analgesic pathways, and modulates the spinal nociceptive transmission. It is NOT a significant peripheral COX inhibitor and has essentially no anti-inflammatory effect at clinical doses.

Key clinical differences:

For acute tension headache in non-pregnant adults, acetaminophen and willow bark produce roughly comparable analgesic effect with different side effect profiles. For migraine, the anti-inflammatory mechanism gives willow a modest theoretical edge over acetaminophen. For pregnancy and breastfeeding, acetaminophen is preferred.

Back to Table of Contents

Combination Protocols for Migraine Prevention

Practitioners add willow bark to multi-component natural migraine prevention protocols, where the goal is reducing attack frequency by 50% or more over 3-6 months of daily use. The components, with the rating each received in the 2012 American Academy of Neurology / American Headache Society guideline on complementary treatments for episodic migraine prevention (Holland 2012):

The combination regimen practitioners describe is magnesium glycinate 400 mg + riboflavin 400 mg + coenzyme Q10 300 mg + feverfew 200 mg + willow bark extract delivering 240 mg salicin, all taken daily, with response judged after 3 months of consistent use. Trial evidence exists for several components individually (above); for willow within a combination it is limited to the small open-label study below.

The only human headache study involving willow found in a PubMed search was a 2006 open-label study with no placebo group: 12 people with migraine without aura took feverfew 300 mg plus white willow 300 mg twice daily for 12 weeks. Attack frequency fell by 61.7% at 12 weeks (a fall seen in nine of the ten who finished), 70% had a drop of at least half, and no adverse events occurred. The authors called for a double-blind, placebo-controlled trial in a larger group (Shrivastava 2006).

For comprehensive non-pharmacologic migraine management see Migraine.

Back to Table of Contents

Medication Overuse Headache

Medication overuse headache (MOH, formerly called "rebound headache") is a real and underrecognized complication of frequent acute headache medication use. It occurs when acute medications taken too often (under the International Classification of Headache Disorders, 3rd edition: on 15 or more days a month for simple pain relievers such as aspirin, acetaminophen or nonsteroidal anti-inflammatory drugs, and on 10 or more days a month for triptans, ergotamines, opioids or combination analgesics, for more than 3 months) themselves induce chronic daily headache.

The mechanism involves central nervous system sensitization, downregulation of endogenous antinociceptive pathways, and rebound vasodilation as the medication wears off. Patients caught in this cycle often increase medication frequency to chase relief, worsening the underlying MOH problem.

Willow bark's role in this context is dual:

The approach practitioners describe: willow bark as a daily prophylactic agent (combined with the magnesium / riboflavin / coenzyme Q10 / feverfew preventive stack), with specific fast-onset agents (triptans for migraine, ibuprofen for tension headache) kept for acute breakthrough symptoms, and acute-medication days kept below the overuse thresholds above (fewer than 10 days a month stays under the threshold for every drug class).

Back to Table of Contents

Dosing for Headache

Back to Table of Contents

Cautions

Back to Table of Contents

Key Research Papers

  1. Diener HC et al. (2005). Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention — a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia. — PubMed PMID: 16232154
  2. Schoenen J et al. (1998). Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. — PubMed PMID: 9484373
  3. Sandor PS et al. (2005). Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. — PubMed PMID: 15728298
  4. Diener HC et al. (2005). The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia, 25(10):776-787. — PubMed PMID: 16162254
  5. Lipton RB et al. (1998). Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Archives of Neurology, 55(2):210-217. — PubMed PMID: 9482363
  6. Kirthi V et al. (2013). Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews. — PubMed PMID: 23633350
  7. Mauskop A, Varughese J (2012). Why all migraine patients should be treated with magnesium. Journal of Neural Transmission, 119(5):575-579. — PubMed PMID: 22426836
  8. Chrubasik S et al. (2000). Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study. American Journal of Medicine, 109(1):9-14. — PubMed PMID: 10936472
  9. Pareek A et al. (2011). Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacognosy Reviews, 5(9):103-110. — PubMed PMID: 22096324
  10. Vlachojannis JE et al. (2009). A systematic review on the effectiveness of willow bark for musculoskeletal pain. Phytotherapy Research. — PubMed PMID: 19140170
  11. Headache Classification Committee of the International Headache Society (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1):1-211. — PubMed PMID: 29368949
  12. Diener HC, Limmroth V (2004). Medication-overuse headache: a worldwide problem. Lancet Neurology. — PubMed PMID: 15261608
  13. Holland S et al. (2012). Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology, 78(17):1346-1353. — PubMed PMID: 22529203
  14. Schmid B et al. (2001). Pharmacokinetics of salicin after oral administration of a standardised willow bark extract. European Journal of Clinical Pharmacology, 57(5):387-391. — PubMed PMID: 11599656
  15. Krivoy N et al. (2001). Effect of salicis cortex extract on human platelet aggregation. Planta Medica, 67(3):209-212. — PubMed PMID: 11345689
  16. Shrivastava R et al. (2006). Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clinical Drug Investigation, 26(5):287-296. — PubMed PMID: 17163262
  17. Shrivastava R et al. (2026). Association of parthenolide and salicin as a preventive treatment on a migraine model induced by dural inflammatory soup application. Pain, 167(2):297-307. — PubMed PMID: 41512309
  18. Stone E (1763). An account of the success of the bark of the willow in the cure of agues. Philosophical Transactions of the Royal Society of London, 195-200. — doi:10.1098/rstl.1763.0033

PubMed Topic Searches

  1. PubMed: Willow bark headache
  2. PubMed: Salicylate headache mechanism
  3. PubMed: Migraine prophylaxis natural supplement
  4. PubMed: Tension headache NSAID
  5. PubMed: Feverfew/riboflavin/magnesium migraine

Back to Table of Contents

Connections

Back to Table of Contents